These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
76 related articles for article (PubMed ID: 2583918)
41. Fluoxetine therapy in obese diabetic and glucose intolerant patients. Kutnowski M; Daubresse JC; Friedman H; Kolanowski J; Krzentowski G; Scheen A; Van Gaal L Int J Obes Relat Metab Disord; 1992 Dec; 16 Suppl 4():S63-6. PubMed ID: 1338388 [TBL] [Abstract][Full Text] [Related]
42. Serotonergic agents in the treatment of hypothalamic obesity syndrome: a case report. Jordaan GP; Roberts MC; Emsley RA Int J Eat Disord; 1996 Jul; 20(1):111-3. PubMed ID: 8807359 [TBL] [Abstract][Full Text] [Related]
43. Fluoxetine differentially alters alcohol intake and other consummatory behaviors in problem drinkers. Naranjo CA; Kadlec KE; Sanhueza P; Woodley-Remus D; Sellers EM Clin Pharmacol Ther; 1990 Apr; 47(4):490-8. PubMed ID: 2328557 [TBL] [Abstract][Full Text] [Related]
44. Fluoxetine-induced weight loss in overweight, nondepressed subjects. Ferguson JM Am J Psychiatry; 1986 Nov; 143(11):1496. PubMed ID: 3535547 [No Abstract] [Full Text] [Related]
45. Is fluoxetine an effective therapy for weight loss in obese patients? Epling J; Am Fam Physician; 2003 Dec; 68(12):2437-8. PubMed ID: 14705765 [No Abstract] [Full Text] [Related]
49. Effect of fluoxetine on weight reduction in obese patients. Afkhami-Ardekani M; Sedghi H Indian J Clin Biochem; 2005 Jan; 20(1):135-8. PubMed ID: 23105511 [TBL] [Abstract][Full Text] [Related]
50. Adverse event frequencies generate hypotheses of efficacy and safety. Goldstein DJ; Wilson MG Clin Pharmacol Ther; 1993 Sep; 54(3):245-51. PubMed ID: 8375120 [No Abstract] [Full Text] [Related]
51. Use of Fluoxetine to Reduce Weight in Adults with Overweight or Obesity: Abridged Republication of the Cochrane Systematic Review. Serralde-Zuñiga AE; González-Garay AG; Rodríguez-Carmona Y; Meléndez-Mier G Obes Facts; 2022; 15(4):473-486. PubMed ID: 35654016 [TBL] [Abstract][Full Text] [Related]
52. What pharmacological interventions are effective in binge-eating disorder? Insights from a critical evaluation of the evidence from clinical trials. Heal DJ; Gosden J Int J Obes (Lond); 2022 Apr; 46(4):677-695. PubMed ID: 34992243 [TBL] [Abstract][Full Text] [Related]
53. Prospects for new drugs to treat binge-eating disorder: Insights from psychopathology and neuropharmacology. Heal DJ; Smith SL J Psychopharmacol; 2022 Jun; 36(6):680-703. PubMed ID: 34318734 [TBL] [Abstract][Full Text] [Related]
54. Fluoxetine for adults who are overweight or obese. Serralde-Zúñiga AE; Gonzalez Garay AG; Rodríguez-Carmona Y; Melendez G Cochrane Database Syst Rev; 2019 Oct; 10(10):CD011688. PubMed ID: 31613390 [TBL] [Abstract][Full Text] [Related]
55. Comparison of paroxetine and agomelatine in depressed type 2 diabetes mellitus patients: a double-blind, randomized, clinical trial. Kang R; He Y; Yan Y; Li Z; Wu Y; Guo X; Liang Z; Jiang J Neuropsychiatr Dis Treat; 2015; 11():1307-11. PubMed ID: 26064049 [TBL] [Abstract][Full Text] [Related]
57. Quality of life and metabolic status in mildly depressed patients with type 2 diabetes treated with paroxetine: a double-blind randomised placebo controlled 6-month trial. Paile-Hyvärinen M; Wahlbeck K; Eriksson JG BMC Fam Pract; 2007 Jun; 8():34. PubMed ID: 17570858 [TBL] [Abstract][Full Text] [Related]
59. Psychotropic drugs in the treatment of obesity: what promise? Appolinario JC; Bueno JR; Coutinho W CNS Drugs; 2004; 18(10):629-51. PubMed ID: 15270593 [TBL] [Abstract][Full Text] [Related]
60. Quality of life and metabolic status in mildly depressed women with type 2 diabetes treated with paroxetine: a single-blind randomised placebo controlled trial. Paile-Hyvärinen M; Wahlbeck K; Eriksson JG BMC Fam Pract; 2003 May; 4():7. PubMed ID: 12747810 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]